KAZIA THERAPEUTICS-SPON ADR (KZIA)
US48669G1058 - ADR
KZIA gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 588 industry peers in the Biotechnology industry. Both the profitability and financial health of KZIA have multiple concerns. KZIA is valied quite expensively at the moment, while it does show a decent growth rate.
1. Profitability
1.1 Basic Checks
KZIA had negative earnings in the past year.
In the past year KZIA has reported a negative cash flow from operations.
KZIA had negative earnings in each of the past 5 years.
KZIA had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
Looking at the Return On Assets, with a value of -72.87%, KZIA is doing worse than 68.21% of the companies in the same industry.
KZIA has a worse Return On Equity (-169.83%) than 68.21% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -72.87% | ||
| ROE | -169.83% | ||
| ROIC | N/A |
ROA(3y)-52.36%
ROA(5y)-51.92%
ROE(3y)-109.65%
ROE(5y)-97.91%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
KZIA does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
The number of shares outstanding for KZIA has been increased compared to 1 year ago.
Compared to 5 years ago, KZIA has more shares outstanding
The debt/assets ratio for KZIA is higher compared to a year ago.
2.2 Solvency
KZIA has an Altman-Z score of -6.45. This is a bad value and indicates that KZIA is not financially healthy and even has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -6.45, KZIA is doing worse than 67.52% of the companies in the same industry.
A Debt/Equity ratio of 0.15 indicates that KZIA is not too dependend on debt financing.
Looking at the Debt to Equity ratio, with a value of 0.15, KZIA is doing worse than 66.32% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.15 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -6.45 |
ROIC/WACCN/A
WACCN/A
2.3 Liquidity
A Current Ratio of 1.42 indicates that KZIA should not have too much problems paying its short term obligations.
Looking at the Current ratio, with a value of 1.42, KZIA is doing worse than 84.96% of the companies in the same industry.
KZIA has a Quick Ratio of 1.42. This is a normal value and indicates that KZIA is financially healthy and should not expect problems in meeting its short term obligations.
Looking at the Quick ratio, with a value of 1.42, KZIA is doing worse than 83.42% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.42 | ||
| Quick Ratio | 1.42 |
3. Growth
3.1 Past
KZIA shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 34.28%, which is quite impressive.
Looking at the last year, KZIA shows a very strong growth in Revenue. The Revenue has grown by 974.29%.
KZIA shows a very negative growth in Revenue. Measured over the last years, the Revenue has been decreasing by -28.31% yearly.
EPS 1Y (TTM)34.28%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q78.19%
Revenue 1Y (TTM)974.29%
Revenue growth 3Y-30.05%
Revenue growth 5Y-28.31%
Revenue growth Q2Q20281.82%
3.2 Future
Based on estimates for the next years, KZIA will show a very strong growth in Earnings Per Share. The EPS will grow by 52.53% on average per year.
KZIA is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 385.92% yearly.
EPS Next Y110%
EPS Next 2Y45.85%
EPS Next 3Y-64.68%
EPS Next 5Y52.53%
Revenue Next Year95807.9%
Revenue Next 2Y2996.9%
Revenue Next 3Y397.46%
Revenue Next 5Y385.92%
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for KZIA. In the last year negative earnings were reported.
KZIA is valuated quite expensively with a Price/Forward Earnings ratio of 40.25.
KZIA's Price/Forward Earnings ratio is rather cheap when compared to the industry. KZIA is cheaper than 95.04% of the companies in the same industry.
KZIA is valuated expensively when we compare the Price/Forward Earnings ratio to 21.53, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 40.25 |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
A cheap valuation may be justified as KZIA's earnings are expected to decrease with -64.68% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y45.85%
EPS Next 3Y-64.68%
5. Dividend
5.1 Amount
No dividends for KZIA!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
KAZIA THERAPEUTICS-SPON ADR
NASDAQ:KZIA (4/16/2024, 12:25:53 PM)
0.2927
-0.01 (-4.66%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap7.72M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 40.25 | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -72.87% | ||
| ROE | -169.83% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.15 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 1.42 | ||
| Quick Ratio | 1.42 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)34.28%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y110%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)974.29%
Revenue growth 3Y-30.05%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y